EVE Health Group LimitedASX: EVE

New Study- GlucoControl Improves Long-Term Glycaemic Control

· Issued by EVE Health Group Limited

Filed with ASX · · 2 pages · English

• University of Adelaide reveals a new global breakthrough for Faulding® GlucoControl for the management of type 2 diabetes • For the first time, a non-pharmaceutical, natural food-based product has demonstrated it can significantly reduce the dangerous blood sugar spikes after a standard meal (converting meals to be “low GI”) and improve overall glycaemic control (HbA1c) in the long term • Fauldi

EVE Health Group Limited on 6ix

Earlier from EVE Health

Later from EVE Health

All EVE Health news releases